{"id":"NCT01240382","sponsor":"Santen Pharmaceutical Co., Ltd.","briefTitle":"Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye","officialTitle":"Double-masked Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Multi-center Study, in Comparison to 0.1% Sodium Hyaluronate Ophthalmic Solution) - Phase III Confirmatory Study -","status":"COMPLETED","phase":"PHASE3","dates":{"start":null,"primaryCompletion":"2008-02","completion":null,"firstPosted":"2010-11-15","resultsPosted":"2014-08-08","lastUpdate":"2014-08-13"},"enrollment":332,"design":{"allocation":null,"model":null,"masking":null,"primaryPurpose":null},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"3% DE-089 ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"0.1% sodium hyaluronate ophthalmic solution","otherNames":[]}],"arms":[{"label":"3% DE-089","type":"EXPERIMENTAL"},{"label":"0.1% HA","type":"ACTIVE_COMPARATOR"}],"summary":"To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.","primaryOutcome":{"measure":"Mean Change in Fluorescein Staining Score From Baseline","timeFrame":"Baseline and 4-week (discontinued (LOCF))","effectByArm":[{"arm":"3% DE-089","deltaMin":-2.12,"sd":1.66},{"arm":"0.1% HA","deltaMin":-2.08,"sd":1.52}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["22914501"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":144},"commonTop":["Eye irritation"]}}